| 发明名称 | Phage derived antimicrobial activities | ||
| 摘要 | The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. | ||
| 申请公布号 | US9622486(B2) | 申请公布日期 | 2017.04.18 |
| 申请号 | US201414278574 | 申请日期 | 2014.05.15 |
| 申请人 | Gangagen, Inc. | 发明人 | Padmanabhan Sriram;Paul Vivek Daniel;Saravanan R. Sanjeev;Sriram Bharathi |
| 分类号 | A01N63/02;A61K38/50;C12N9/36;C07K14/00;C12N1/20;C12N9/78 | 主分类号 | A01N63/02 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A sterile pharmaceutical composition comprising a pharmaceutically acceptable excipient and a chimeric polypeptide comprising: (i) a first sequence having at least 90% identity to the sequence of amino acids 669-808 of SEQ ID NO:1; and (ii) a heterologous cell binding domain (CBD) that binds to a target bacterium, wherein the CBD has a sequence with at least 90% identity to a sequence selected from the group consisting of: amino acids 144-240 of SEQ ID NO:4, amino acids 149-257 of SEQ ID NO:8, and amino acids 144-243 of SEQ ID NO:12; wherein the target bacterium exhibits reduced or no growth after being contacted with the sterile pharmaceutical composition. | ||
| 地址 | Newark CA US | ||